150O Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions
Titel:
150O Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions
Auteur:
Hong, D.S. Dowlati, A. Burris III, H.A. Lee, J.J. Brose, M.S. Farago, A.F. Bauer, T.M. Taylor, M. Shaw, A.T. Smith, S. Nanda, N. Cruickshank, S. Cox, M.C. Doebele, R.